When cancer enters what is commonly referred to as the “stable phase,” many patients and their families may mistakenly believe that the disease is over and requires no further vigilance. However, in clinical practice, we often see that cancer cells can remain dormant for years and that metastasis may occur silently. This stage is, in fact, a critical window for prevention and monitoring.

Why “Stable” Doesn’t Mean “Cured”

The term “stable” usually refers to a condition where there’s no significant progression in imaging studies or tumor markers. Yet this is only a superficial stability. Research has shown that even when visible lesions are under control, microscopic circulating tumor cells (CTCs) or cancer stem cells may still exist in the body, possessing high potential for recurrence and metastasis.

How Can We Assess the Risk of Metastasis?

1. Circulating Tumor Cell (CTC) Detection
CTCs are cells that detach from the primary tumor and enter the bloodstream. They are considered a precursor to metastasis. With advanced technologies—such as the RGCC platform for CTC analysis—we can not only quantify CTCs but also evaluate their response to various natural compounds and drugs, helping physicians design personalized prevention strategies.

2. Tumor Genetic and Immune Profiling
Some metastases are closely linked to specific mutations or suppressed immune environments. Comprehensive molecular testing can help identify hidden risks and determine suitable interventions, including nutritional support, immune restoration, or natural compound supplementation.

Strategies for Proactive Management

• Regular Monitoring and Data Tracking: Don’t rely solely on imaging. CTC and biomarker monitoring every 3 to 6 months offers more sensitive risk evaluation.
• Lifestyle and Nutritional Interventions: Adjusting diet, sleep, and stress levels—combined with nutrient plans tailored to individual metabolism and constitution—can improve the tumor microenvironment.
• Natural Support Compounds: Certain natural agents such as resveratrol, fucoidan, and reishi mushroom have shown inhibitory effects on metastatic cells in laboratory studies and may be used under professional guidance.

Final Thoughts

The stable phase of cancer is not an endpoint—it’s a crucial stage that requires thoughtful strategy and careful attention. By identifying risks early and implementing evidence-based nutritional and physiological measures, we can take proactive steps to protect long-term health and reduce the likelihood of recurrence.

References:

1. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–424.
2. Gazzaniga P, Raimondi C. Monitoring of cancer cell dissemination in peripheral blood: the clinical relevance of circulating tumor cells. Cancer Lett. 2013;338(2):345–351.
3. RGCC Group. CTC & Immune Profiling Services. www.rgcc-group.com
4. Yu M, et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192(3):373–382.

Medical Disclaimer:

The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM THAT YOU HAVE ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.